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Abstract
Arrhythmias play a significant role in the mortality and morbidity as well as hospitalizations
of patients who carry a diagnosis of congestive heart failure. With improving survival in a world
of novel medications and devices, an understanding of the pathophysiology and management
of these arrhythmias is crucial. Majority of the basic heart failure medications such as beta-
-blockers, angiotensin converting enzyme inhibitors/aldosterone receptor blockers and aldo-
sterone antagonists play a pivotal role in prevention of sudden cardiac deaths which can be
a direct/indirect result of these arrhythmias. Anti-arrhythmic drugs and implantable cardioverter-
-defibrillators were also beneficial in selected patients. Innovative electrophysiological techniques
need to be considered in special situations. (Cardiol J 2012; 19, 6: 567–577)
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Introduction
Heart failure (HF) is a progressively increas-
ing epidemic of this century with an estimated
5.2 million American (2.5%) currently being affect-
ed by it [1–3]. One in 5 adults greater than age for-
ty will develop HF in their lifetime with an estimat-
ed direct and indirect health care burden of $33.2
billion [3, 4]. The rate of hospitalizations due to/or
involving HF is progressively increasing (tripled
from 1979 to 2004), making it currently the most
common reason for admission in the elderly [5, 6].
Arrhythmias play a major role in these frequent hos-
pitalizations and office visits. Sudden cardiac death
(SCD), a common result of arrhythmias contribute
to more than 30–50% of all-cause mortality in pa-
tients classified as New York Heart Association
(NYHA) II–III [7]. Hence, an in-depth understand-
ing of the concepts which aide in its management
is of prime importance.
Majority of the abnormal heart rhythms gene-
rally tend to occur in patients with reduced left
ventricular (LV) systolic function even though their
presentation in HF with preserved ejection fraction
(HFpEF) is not uncommon [8]. Arrhythmias en-
countered in HF are diverse but ventricular fibril-
lation (VF) and pulseless ventricular tachycardia
(VT) are responsible for SCD in this cohort [9].
Atrial fibrillation (AF) and atrial flutter (AFL) are
frequently associated with worse hemodynamic
compromise in HF patients. Moreover, they are
generally related to factors which enhance triggered
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arrhythmias, when compared to patients without
HF [10].
With the advances in HF management preven-
tion of arrhythmias is gaining greater significance.
However, the currently available antiarrhythmic
drugs have some limitations due to their side ef-
fects profile and proarrhythmic effect. The efficacy
of implantable cardioverter-defibrillators (ICD) in
preventing SCD had revolutionized the manage-
ment strategies in the subgroup of patients with low
left ventricular ejection fraction (LVEF) [11]. How-
ever, this therapy is not free of complications such
as inappropriate shocks, advisories, and driving
limitations [12–15].
Hence, we made an effort to outline the current-
ly available studies and literature in this field with
intent to guide a practicing physician in managing
these complex arrhythmias in HF. All the recom-
mendations will be grounded upon evidence-based
medicine. However, therapy in any particular HF
patient should be individualized, since each patient
presents with unique set of challenges dictated by
the particular arrhythmia, symptoms, co-morbidities,
genetics and personal treatment preferences.
Current standard heart
failure medications
Standard HF medications such as beta-block-
ers (BB), angiotensin converting enzyme (ACE)
inhibitors and aldosterone receptor blockers
(ARBs) have shown significant reduction in the risk
of SCD. There are numerous trials done on these
medications, but only a few of these directly ad-
dressed the impact on SCD. While the treatment
and prevention of SCD demands specifically target-
ed therapy, this background standard medical
therapy must not be ignored.
Beta-blockers
The use of BB in patients with chronic HF had
been associated with improved morbidity and LV
function in multiple trials some of which also report-
ed their specific impact on SCD. The MERIT-HF
study showed that metoprolol succinate reduced the
all-cause mortality by 34%, mortality due to sud-
den death by 41% and mortality due to progression
of HF by 49% (Fig. 1) [7, 16]. Similarly, it was evi-
dent from the Cardiac Insufficiency Bisoprolol Study
II (CIBIS–II) trial (which included equal number of
ICM or NICM patients as well as NYHA III–IV) that
bisoprolol reduced the risk of SCD by 41% (34%
reduction total mortality) [17]. The US Carvedilol
Heart Failure Study Group have shown that use of
carvedilol (a non-selective blocker of beta-1 and
alpha-1 receptors) for HF resulted in a 56% reduc-
tion in SCD [18]. The COMET study demonstrat-
ed a further 3% absolute reduction of SCD in
carvedilol group compared to metoprolol tartrate
(14% vs. 17%) [19]. Overall, there is 40–50% rela-
tive risk reduction or 4.4% absolute reduction in
SCD with the use of BB.
ACE inhibitors
The importance of the effect of ACE inhibitors
is very clear in light of trials highlighting their sig-
nificant benefit in preventing SCD. The Vasodila-
tor Heart Failure trial II (V-HEFT II) showed that
the use of enalapril was associated with 39% reduc-
tion in SCD compared to the use of a combination
of hydralazine/isosorbide dinitrate [20]. The AIRE
Trial (Acute Infarction Ramipril Efficacy) showed
that use of ramipril resulted in 27% reduction in
SCD at 15 months vs. placebo [21]. Use of ramipril
in the HOPE (Heart Outcomes Protection Evalua-
tion) trial demonstrated a 21% reduction in SCD in
patients classified as HF Stage A [22]. The TRACE
(Trandolapril Cardiac Evaluation) (post AMI, EF
< 35% vs. placebo at 24–50 months) showed that
trandolapril did reduce SCD by 24% (Fig. 2) [23].
Overall there is 20–40% relative risk reduction of
SCD with the use of ACE inhibitors.
Angiotensin receptor blockers
Major trials involving ARBs including the Val-
HeFT, CHARM and VALIANT had mixed results
on mortality benefits when compared to the ACE
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Figure 1. Effect of metoprolol in preventing sudden car-
diac death (MERIT-HF study)
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inhibitors and none of them specifically addressed
their impact on SCD [24–26].
Aldosterone antagonists
The RALES (Randomized Aldactone Evalua-
tion Study) revealed that spironolactone was asso-
ciated with a 29% risk reduction of SCD (overall
30% reduction at 2 years) [27]. Preventing cellular
efflux and overall loss of magnesium has been pro-
posed as the potential mechanism [28]. In addition,
the EPHESUS (Eplerenone Post AMI Heart failure
Efficacy trial) proved that eplerenone also carried
a similar benefit with an overall reduction of SCD
by 21% (Fig. 3). Necessity of aldosterone antago-
nism in chronic severe systolic HF as well as HF
after myocardial infarction has been proven beyond
doubt [29]. Of late, there is growing evidence sup-
porting the use of aldosterone antagonists even in
mild systolic HF in an effort to prevent SCD [30].
Overall, there is a 20–30% risk reduction of SCD
by using aldosterone antagonists.
Antiarrhythmic drugs
All antiarrhythmic drugs possess potential
proarrhythmic toxicity and in general class IA and
IC drugs are contraindicated in HF patients. Class
III agents such as amiodarone, dofetilide and azi-
milide have a low incidence of ventricular proar-
rhythmias (Table 1) [31]. A recent meta-analysis
showed that amiodarone reduces the risk of SCD
by 29% and cardiovascular disease by 18%, and
therefore, represents a viable alternative in patients
who are not eligible for or who do not have access
to ICD therapy for the prevention of SCD. This drug
can be considered as adjuvant therapy to ICD in
preventing recurrent shocks [32]. However, amio-
darone therapy is neutral with respect to all-cause
mortality and is associated with a 2 and 5 fold in-
creased risk of pulmonary and thyroid toxicity re-
spectively [33]. Dofetilide and azimilide did not
demonstrate a mortality benefit either [34–36]. In
summary, there is little role for prophylactic anti-
arrhythmic medications for the primary prevention
of SCD in patients with HF except amiodarone. The
benefits of the ICDs demonstrated to be superior
to the effect of antiarrhythmic drugs for primary
prevention of SCD.
Implantable cardioverter-defibrillator
ICDs have gained a lot of popularity in the
management of SCD replacing the use of antiar-
rhythmic drugs in primary prevention and relegat-
ed their role as co-adjuvant treatment for reducing
the incidence of appropriate (or inappropriate incase
of AF) shocks in patients with pre-existing ICDs
[32]. It uses antitachycardia pacing (ATP), cardio-
version, defibrillation and pacing for bradycardia to
achieve its goal. Trials that looked at primary pre-
vention using ICDs mainly included patients with
EF < 35% and NYHA class II–IV. From all these
trials, it was evident that patients who have EF
< 35% and experiencing NYHA class II–III symp-
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Figure 3. Sudden cardiac death in EPHESUS trial, com-
paring patients randomized to the selective aldostero-
ne antagonist eplerenone versus placebo.
Figure 2. Effect of trandolapril in preventing sudden
cardiac death (TRACE trail)
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toms despite optimal medical therapy are at high
risk of SCD and thus this population will benefit
with the use of an ICD (Table 2) [37–40].
Given the significant increase in use of ICDs,
a clear understanding of scenarios when they de-
liver therapy and management of arrhythmias in
these situations is crucial.
ICD shocks
Patients implanted with ICDs will experience
shocks occasionally, which can be distressful. Atten-
tion needs to be paid to psychological and emotional
consequences of ICD therapies. Some of the patients
may refer a shock when in fact the device did not
deliver therapy. Interrogation of the device is man-
datory, not only to confirm the type of delivered ther-
apy, but also to reassure the patient on how to react
when a shock occurs. Initial evaluation of the patient
who has received ICD discharges should focus upon
any possible precipitants for arrhythmias, including
electrolyte disturbances, myocardial ischemia/infarc-
tion, worsening HF or drug toxicities. Device inter-
rogation will allow proper classification of the shock
(appropriate vs. inappropriate).
Appropriate shocks is the one delivered for
VT/VF. Recurrent appropriate shocks (also known
as “electrical storm”) need immediate medical at-
tention, since it can lead to reduced survival [41,
42]. These patients are also at increased risk for
non-SCD due to progression of ventricular dysfunc-
tion. Efforts to decrease device therapies should
include programming ATP to terminate VT and the
use of drugs to prevent VT in addition to the ICD
[32]. ATP is a painless technique which involves
detection of VT and timely delivery of rapid sequen-
tial ventricular pacing at rates, thereby overriding
the underlying arrhythmia [43]. Patients who re-
ceive appropriate shocks were noted to have sub-
stantially higher ventricular arrhythmia burden and
poor survival compared to patients treated with
ATP-alone [44]. Adjunctive pharmacotherapy, in
addition to ATP, was shown to reduce the incidence
of shocks. Amiodarone along with BB reduced the
incidence of shocks from 41% to 29% compared to
BB alone [32]. However, celivarone a new noniod-
inated benzofuran derivative with an action similar
to amiodarone failed to show similar benefit of re-
ducing appropriate ICD therapies or SCD [45]. Use
of sotalol was noted to decrease shock free survi-
val by 49% compared to placebo. Azimilide was also
shown to decrease the number of symptomatic ar-
rhythmias treated by ATP/shock therapy in addi-
tion to reducing Emergency Room visits and hos-
pitalizations [46, 47]. Recurrent arrhythmias lead-
ing to appropriate shocks should prompt adequate
evaluation for undiagnosed ischemia as the culprit
with a possibility of revascularization as needed. Fi-
nally, VT ablation should also be considered in or-
der to modify the anatomical substrate, reducing the
number of ICD discharges [48].
Inappropriate shocks/atrial fibrillation/
/atrial flutter. Sometimes ICD can misread other
rhythms as VT/VF especially when the rate of the
on-going arrhythmia is greater than the pre-set
detection rate of the ICD. In this scenario, the ICD
can deliver a shock, which is labelled as inappro-
priate. Inappropriate ICD shocks were associated
with increased risk of all-cause mortality [42, 49].
The most common cause for these shocks are AF/
/AFL [49]. AF and HF are commonly encountered
together, either condition predisposing to the oth-
er. The presence of each condition increases the
morbidity and mortality associated with the other
and their coexistence complicates patient manage-
ment [50]. Of the 2 principal therapeutic strategies
in managing AF, rate control and rhythm control,
neither has been shown to be superior to the other
in terms of survival, despite better quality of life and
LV function in patients with sinus rhythm compared
to those in AF (Table 3) [51, 52]. Patients with ICD
are preferred to be in sinus rhythm, to prevent in-
appropriate shocks and readmissions. If a cardiover-
sion is planned, it is recommended that all patients
undergo transesophageal echocardiogram to rule
out left atrial thrombus and preferred to be fully an-
ticoagulated for at least 3 weeks prior the planned
procedure. Anticoagulation has to be continued for
at least 4–6 weeks after cardioversion despite restor-
ing a normal rhythm. The use of antiarrhythmic
agents after cardioversion can help maintain sinus
rhythm and prevent inappropriate shocks [53]. Amio-
darone along with BB reduces the incidence of in-
appropriate shocks from 41% to 29% compared to
BB alone [54]. Digoxin can be used in patients with
permanent and persistent AF as a rate control strat-
egy in order to prevent inappropriate shocks [55].
Catheter ablation of AF is a newer technique
that should be considered in a selected population
of patients with HF. Atrio Ventricular Junction Ab-
lation (AVJA) and pulmonary vein isolation are the
two predominant ablation strategies used to treat
AF patients who are refractory to drugs. In patients
with congestive HF refractory to drugs, AVJA with
biventricular pacing (BiV) for cardiac resynchroni-
zation has shown an improvement in exercise ca-
pacity and quality of life [56]. Overuse of right
ventricular (RV) pacing alone in scenarios such as
AVJA has a tendency to increase threshold for
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shocks as well as cause HF exacerbation [57, 58].
When compared to RV apical pacing alone, BiV pac-
ing resulted in improvement in LVEF [59]. How-
ever, in a head-to-head comparison, pulmonary vein
antrum ablation was shown to be superior to AVJA
[60]. Cure of AF in patients with congestive HF re-
sulted in more significant morphological and func-
tional improvements than AVJA [60]. Restoration
and maintenance of sinus rhythm by catheter abla-
tion without the use of drugs in patients with con-
gestive HF and AF significantly improve cardiac
function, symptoms, exercise capacity, and quality
of life (Table 4) [50, 61, 62].
Cardiac resynchronization therapy
Patients with NYHA class III–IV who has QRS
prolongation more than 120 s and EF < 35%, were
noted to benefit from cardiac resynchronization
therapy (CRT) when used in conjunction with ICD
(CRT-D) (recent data suggest that the benefit is
more pronounced when the QRS duration is longer
than 150 ms) [63–65]. CRT-D in COMPANION trial
showed reduction of SCD by 56% compared to CRT
alone. These benefits were not reflected in NYHA
class I–II patients in the RAFT trial [66]. However,
a specific subgroup of patients with NYHA class I–II
(LVEF £ 30%) and a left bundle branch block
(LBBB) were noted to derive significant benefit from
CRT-D with reduction in HF progression as well as
a reduction in the risk of ventricular tachyarrhyth-
mias [67]. Patients with CRT also seem to have less
recurrence of AF, which is attributed to atrial re-
verse-remodeling and a shorter AF duration [68].
Non-ICD population
Patients diagnosed of HFpEF and advanced HF
(NYHA IV) patients where ICD is not indicated can
be considered under this category. Previous studies
have indicated that this cohort constitutes 1.2% of
all the patients with HFpEF and are at eight times
greater risk of death [69]. These patients have pre-
served systolic function without known scar or fibrot-
ic tissue burden, which is considered a potential sub-
strate for arrhythmias in the systolic HF group. They
have an annual death rate of 5.6% per the observa-
tions in I-PRESERVE HFpEF cohort of which 26%
are due to sudden death [70]. Multiple hypotheses
have been proposed to explain this pathological pro-
cess [71], however consensus has not been reached
so far making treatment plans complex. The mana-
gement of arrhythmias in this cohort can be divided
into ventricular and supraventricular arrhythmias.Ta
b
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Ventricular arrhythmias
Optimization of medical treatment should in-
clude BB, ACE inhibitor/ARBs and aldosterone
antagonists in order to prevent SCD. Amiodarone
is a useful addition in preventing SCD in patients
with advanced HF. However, its side effect profile
needs to be closely monitored. Atorvastatin thera-
py was associated with decreased incidence of SCD
in patients with advanced chronic HF [72]. How-
ever, larger on-going studies are needed to confirm
this hypothesis.
Supraventricular arrhythmias
Atrial fibrillation is by far the most frequent
arrhythmia in this clinical scenario. Major progress
has been made in the management of AF in the last
few years with multiple new medications joining the
currently existing armamentarium of amiodarone,
digoxin, BB and calcium channel blockers. The
ADONIS (American-Australian-African study) and
European Trial EURIDIS, both controlled trials with
over 600 patients each, showed that dronedarone
is significantly more effective than placebo in main-
taining sinus rhythm and in reducing the ventricu-
lar rate during recurrence of AF [73, 74]. Drone-
darone also reduced the incidence of hospitalization
due to cardiovascular events or death in patients
with AF [75]. However, in patients with severe HF
and LV systolic dysfunction (NYHA III–IV), treat-
ment with dronedarone was associated with in-
creased early mortality related to the worsening of
HF [76] and hence is contraindicated. A recent
study also showed increase in major cardiac events
with its use in patients with permanent AF [77].
Azimilide in the ALIVE study also showed a de-
crease in the incidence of AF by 50% [78]. Dofeti-
lide in DIAMOND HF was shown to be safe along
with decrease in HF readmissions by 21%, which
was speculated to be through decrease in the inci-
dence of AF [79].
GISSI-HF study revealed a beneficial effect of
rosuvastatin in reducing the incidence of AF in pa-
tients with HF. Larger studies are needed to pro-
vide a definitive answer to this question [80]. An
ovine HF study showed chronic n-3 PUFAs use
protected against adverse atrial remodeling by pre-
venting atrial enlargement, fibrosis and conduction
abnormalities leading to shorter AF episodes [81].
Newer management strategies
A resting heart rate above 70 bpm is an inde-
pendent risk factor in systolic HF [82]. If this high
heart rate persists despite the maximal tolerated
BB dose, isolated heart rate reduction by ivabradine
may lower the rate of hospital admissions due to
worsening HF [83]. Iron deficiency should be cor-
rected independently of the presence of anemia to
improve symptoms and exercise capacity. Since
sodium overload play an important role in the patho-
physiology of HF, the use of ranolazine which blocks
late sodium current is currently being studied for
reduction of cardiac arrhythmias [84].
Arrhythmias and mechanical
circulatory support
There is growing cohort of patients with ad-
vanced HF currently being managed on mechani-
cal circulatory support. These patients are at great-
er risk of arrhythmias of both atrial and ventricular
origin especially post surgery [85, 86]. Increase in
filling pressures, mitral and tricuspid regurgitations
leading to chamber remodeling and the presence of
inflow cannula in the LV are some of the inciting
pathophysiological mechanisms proposed to explain
this surge in events. Management of atrial arrhyth-
mias remain the same as with other HF patients.
Table 4. Summary of outcomes in trials involving catheter ablation strategy for atrial fibrillation in pa-
tients with heart failure.
Study No. Baseline NYHA Mean follow up Success Change in Exercise Quality
 class (months) (%) LVEF (%)  capacity  of life
HSU 58 2.3 ± 0.5 12 78 35–56 Improved Improved
Chen 94 Class II: 30% 14 73 36–41 N/A Improved
Class III: 68%
Class IV: 2%
Tondo 40 2.8 ± 0.1 14 87 33–47 Improved Improved
Gentlesk 67 N/A 20 86 42–56 N/A N/A
Abbreviations as in Table 1
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Ventricular tachycardias in this setting are gener-
ally managed by lowering the left ventricular assist
device speeds along with BB and antiarrhythmic
drugs such as amiodarone, dofetilide or mexilitine
[87]. However, the rates of arrhythmias usually
come down farther from the implant allowing scal-
ing down the use of antiarrhythmic drugs. In very
rare situations mechanical circulatory support is
considered in management of patients with refrac-
tory ventricular arrhythmias who failed multiple at-
tempts of medical therapy and ablations.
Conclusions
Management of arrhythmias in patients with
HF remains a challenge. This field is constantly
evolving and the addition of newer techniques and
medications do not stop growing. This brief review
was intended to provide a guide to the practicing
physicians based on currently available evidence.
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